Table 1 Comparison of severe non-fatal and fatal cases, by test-positive status and entry to critical care
Non-fatal | Fatal | |||
|---|---|---|---|---|
Test-positive | No positive test | |||
Critical care, non-fatal (462) | Critical care, fatal (240) | No critical care, fatal (2223) | No critical care, fatal (1310) | |
Age [median (IQR)] | 59 (50.25–65) | 65.5 (58–73) | 83 (76–88) | 84 (76–89) |
Males | 305 (66%) | 187 (78%) | 1111 (50%) | 586 (45%) |
Care home | 4 (1%) | 1 (0%) | 1051 (47%) | 838 (64%) |
Any prescription | 412 (89%) | 223 (93%) | 2180 (98%) | 1280 (98%) |
Any admission | 253 (55%) | 161 (67%) | 1932 (87%) | 1092 (83%) |
Type 1 diabetes | 10 (2%) | 2 (1%) | 22 (1%) | 8 (1%) |
Type 2 diabetes | 90 (19%) | 61 (25%) | 503 (23%) | 251 (19%) |
Other/unknown type | 13 (3%) | 6 (2%) | 22 (1%) | 7 (1%) |
Ischaemic heart disease | 45 (10%) | 31 (13%) | 559 (25%) | 269 (21%) |
Other heart disease | 63 (14%) | 45 (19%) | 1062 (48%) | 570 (44%) |
Asthma or chronic airway disease | 117 (25%) | 65 (27%) | 799 (36%) | 445 (34%) |
Chronic kidney disease or transplant recipient | 6 (1%) | 5 (2%) | 62 (3%) | 23 (2%) |
Neurological (except epilepsy) or dementia | 20 (4%) | 18 (8%) | 801 (36%) | 542 (41%) |
Liver disease | 1 (0%) | 4 (2%) | 30 (1%) | 15 (1%) |
Immune deficiency or suppression | 5 (1%) | 4 (2%) | 24 (1%) | 6 (0%) |